Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Research & Development Clinical Trials Neurology

Ulotaront Phase III Schizophrenia Setback For Sumitomo, Otsuka Alliance

'High Placebo Response'

  • Analysis

Executive Summary

Novel psychiatric drug has missed its Phase III efficacy endpoint in two Phase III trials, posing a potential blow to the Japanese firms' alliance plans in schizophrenia, although development in other CNS indications looks set to continue. 

You may also be interested in...



Sunovion’s TAAR1 Agonist Brings Something New To CNS Arena

Sunovion’s new schizophrenia candidate is generating investor attention given its first-in-class mode of action. Newly published clinical results appear to bear out its promise in a sector where there’s been limited innovation.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner.

Quick Listen: Scrip's Five Must-Know Things

 In this week's podcast edition of Five Must-Know Things: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign.

Table

View full table

Topics

Related Companies

Tags:
Research & Development Clinical Trials Neurology
Latest Headlines

Radiopharmaceutical Leader ITM Gets A Burst Of Energy – And Weighs Up Going Public

Efficacy, Not Safety, Does For Merck KGaA’s BTK Inhibitor

AstraZeneca Likes What Chinese Innovation Has To Offer

Astellas Exec On Tech Tools For Better Go-No-Go Decisions, Gen AI

See All
UsernamePublicRestriction

Register

SC148797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By